Smarter pharmacovigilance operations to quickly navigate through the pandemic
The NELP platform was developed at an opportune time to help our client with their pharmacovigilance practices. As the COVID-19 pandemic continues to evolve with increasing speed, thereby prompting a rapid response from pharmaceutical organizations, it was absolutely essential to leverage every available automation technology to accelerate the pace of breakthroughs and optimize operations within the medical research community. The only real way to do that is by employing intelligent systems that can offload some of the work from human researchers, thereby enabling the latter to focus on synthesizing solutions.
Surprisingly, the NELP platform’s capabilities granted it a degree of versatility that we hadn’t initially expected. As the product combines analytics, machine learning, and natural language processing along with the ability to deliver at scale, it found use cases that transcended all aspects of pharmacovigilance. It has helped with Eudravigilance, legal cases, discovery sciences, target liability assessments, consumer call centers, and a slew of other areas.
Liked this transformation story?
Let's build yours now.
These wide-ranging applications means that the NELP is more than just a tool, but a fully integrated enabler with transformative effects that have enhanced the organization in nearly all aspects. Such an achievement was sorely needed in light of the current state of clinical teams that work round the clock to contain the COVID-19 pandemic.
Effective lead discovery for high-value biological insights
The success of any given trial begins with a trouble-free detection exercise. Identifying the kind of leads that would necessitate work later on means that teams need the potential to extract high-value biological insights. This needs to be done at scale during emergency situations such as a pandemic. Our NELP platform enables this via high content imaging and transcriptomics technologies, thereby helping teams succeed in effective lead discovery.
Efficient data mining of medical literature for effective drug and clinical insights
Once meaningful leads are generated (and this number can run in the thousands, if not millions), teams are faced with yet another dilemma that has historically contributed to the slow pace of drug development: target selection. The only constraint here is processing abilities, and this can be remedied by the use of our NELP platform. It facilitates the mining of very large data sets of medical literature, enabling the discovery of the right target, molecule, and clinical plan.
Accelerated drug discovery and productivity improvements of 50%
The NELP platform’s integrated machine learning operations solution succeeded in reducing the cycle time while concomitantly improving the NME quality across all therapeutic areas. This translated to the enablement of 3.4 billion compound predictions that were a result of over 1000 machine learning models and over a 120 high-scale AI workflows. These combined results also contributed to a whopping 50-60% increase in the productivity of medicinal chemists.
Touchless decision making
Going beyond the detection and selection face, we also helped our clients in the area of expediting their first-in-human decisions through our touchless data integration solution. This support was also extended to advanced tox analytics for therapeutic areas, non-clinical studies as well as safety scientists. NELP was also leveraged for COVID-19 analytics on global published literature and sparked a vaccine digitization and analytics transformation program.
Robust risk management of clinical trials
For purely clinical solutions, our NELP platform was able to leverage the COVID-19 clinical ops risk predictor, and along with SIROP, our AI solutions enabled the reinstating of over 500 global clinical trials. This was made possible due to the generation of over 4000 machine learning models in the course bringing tangible business impact.
Improved compliance in pharmacovigilance and regulatory affairs
As clinical trials continue to be heavily subject to eudravigilance norms, our NELP platform eased our clients’ regulatory burdens by successfully executing automated HA intakes, IDMP extractions. This level of automation was also extended to country-level submissions by leveraging the platform’s MLOPS and NLP capabilities. Through these capabilities alone, we were confident in establishing the realization of a $2.5MM roadmap for 2021.
High-volume of accurate literature case processing in pharmacovigilance
Our NELP platform’s literature automation tool has processed more than 250,000 different pieces of medical literature to predict a grand total of 13,247 cases with a staggering 97% accuracy. Doing this for our client unlocked north of $2MM value via cognitive automation on literature, Eudravigilance, NSNI cases, consumers, Bolus, and business partner cases. The present level of automation alone touches over 100,000 - 150,000 cases.
AI, machine learning, automation, and NLP for pharmacovigilance transformation